Comment on CMS-2026-1256-0002

Summary: CellTrans Inc., the manufacturer of Lantidra, supports the proposal to move islet cell procedures out of kidney-related MS-DRGs but opposes the specific plan to consolidate them into MS-DRG 010. They argue that MS-DRG 010 does not account for the high commercial acquisition costs of manufactured cellular biologics and request the creation of a dedicated MS-DRG or a specific cost-adjustment factor to ensure hospital reimbursement covers the product's cost.